Bristol Taxol Increases Median Survival For Ovarian Cancer By 11 months
Executive Summary
Bristol-Myers Squibb's Taxol in combination with cisplatin increases median survival compared with a cyclophosphamide/cisplatin regimen in ovarian cancer patients, data presented March 20 to FDA's Oncologic Drugs Advisory Committee show.